US10226433B2 – March 12, 2019 – Use of cannabinoids in the treatment of degenerative skeletal muscle diseases

Please complete the required fields.




Inventors :

Vincenzo Di Marzo; Colin Stott; Keith Foster; Fabio Iannotti

Owner :

GW RESEARCH LIMITED, UNITED KINGDOM GW PHARMA LIMITED, UNITED KINGDOM

Application Number :

US15518297

Document Number :

US10226433B2

Priority Date :

October 14, 2014

Filing Date :

October 14, 2015

Date of Grant/ Publication :

March 12, 2019

Class :

A61K31 / 05; A61P21 / 00; A61K31 / 352; A61K36 / 185; A61K45 / 06; A61K31 / 015; A61K31 / 047

Abstract

The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).

Claim(s)

1. A method of treating a subject suffering from Duchenne muscular dystrophy (DMD) comprising administering cannabidiol (CBD) to the subject in need thereof, wherein the CBD is highly purified.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login